QUOTED. 11 November 2020. Grady Hannah.
The US FDA has authorized Nightware, a digital therapeutic that helps reduce sleep disruption in patients with PTSD or nightmare disorder. Nightware Inc. CEO Grady Hannah praised the move.
“In addition to a lack of approved treatment for PTSD-associated nightmares, the FDA’s blessing establishes that this is a serious public health issue and confirms the clinical benefit at a low level of risk for users.” – Grady Hannah, CEO, Nightware Inc.
Click here for a free trial of Medtech Insight